(Q44982532)

English

Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications

scientific article published on 22 March 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

sexual dysfunction

1 reference

based on heuristic

inferred from title

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author name string

Seftel A

1

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rosen R

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Kuritzky L

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

22 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

International Journal of Impotence Research

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

386-392

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Health-related quality of life associated with lower urinary tract symptoms in four countries.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sexual dysfunction in men with lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sexual function in patients with LUTS suggestive of BPH.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Intimacy and quality of life among sexually dysfunctional men and women.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Management of symptomatic BPH in the US: who is treated and how?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Management of symptomatic BPH in France: who is treated and how?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Quality control in the screening of erectile dysfunction--results of a survey

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

The multinational Men's Attitudes to Life Events and Sexuality (MALES) Study Phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

Sildenafil influences lower urinary tract symptoms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

21 January 2018

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Sexual functioning in a population-based study of men aged 40-69 years: the good news

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Under-reporting of erectile dysfunction among men with unrelated urologic conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Erectile dysfunction--the effect of sending a questionnaire to patients on consultations with their family doctor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901540

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.IJIR.3901540

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44982532&oldid=2207025498"